9th Annual Biomarkers Congress

View Profile


Grant Support

Start year End year Title Source Position
1. 2011 Effects of UV irradiation on the immune system N.H. & M.R.C PI
2. 2011 Targeting pro-survival Innovation mechanisms to sensitise Cancer melanoma to immunotherapy Grant, NSW Institute Prof. P. Hersey
3. 2011 Overcoming adaptation to endoplasmic reticulum stress to sensitize melanoma to chemotherapy NHMRC Program Grant Prof. Kefford,Prof. J. Thompson,Prof. P. Hersey,Prof. G. Mann,Prof. R. Scolyer,Dr. N. Haywood
4. 2010 2011 Transcriptional regulation of Mcl-1 during ER stress in Aus Melanoma NHMRC China Prof. P. Hersey,Dr. X.D. Zhang,Dr. X.D. Zhang(Exchange)
5. 2010 2011 Molecular determinants of risk, progression and treatment response in melanoma NH&MRC Program Grant PI
6. 2009 2011 Targeting p53 isoforms to Promote chemosensitivity Council In human melanoma NSW State Cancer Dr. X.D. Zhang,Dr. P. Hersey
7. 2009 2011 Targeting p53 isoforms D40p53 and p53β, to promote chemo-sensitivity in human melanoma NHMRC Project Grant Dr. X.D. Zhang,Prof. P. Hersey,Dr. R.F. Thorne
8. 2009 2011 The role of p53 isoforms in chemoresistance of human melanoma State Cancer Council NSW Project Grant Dr. K.A. Kiejda,Dr. X.D. Zhang,Prof. P. Hersey
9. 2010 Melanoma Institute Australia Translational Research Program Cancer Institute NSW,10/TPG/1-02 Program Grant Prof. G. Mann,Prof. J. Thompson,Prof. R. Kefford,Prof. R. Scolyer,Prof. P. Hersey,Prof. S. Menzies,Dr. A. Spillane,Dr. H. Rizos,Dr. X. D. Zhang ,Prof. R. Christopherson
10. 2010 The role of micro RNA-149 In regulation of Mcl-1 in ER Stress Cure Cancer Australia Dr. C.C. Jiang,Dr. X.D. Zhang,Prof. P. Hersey
11. 2010 Molecular determinants of risk, progression and treatment response in melanoma Research Dr. X.D. Zhang
12. 2006 2010 Molecular genetics of Melanoma predisposition Cancer Institute, NSW PI
13. 2009 Roles of the endoplasmic reticulum and lysosome in TRAIL-mediated killing of melanoma Cure Cancer Australia Foundation Dr. X.D.Zhang
14. 2009 The microRNA signature of Mitchell endoplasmic reticulum stress in human melanoma Wig Week Project Grant Dr. K.A. Kiejda,Prof. P. Hersey,Dr. X.D. Zhang
15. 2009 Targeting p53 isoforms delta-40p53 and p53-beta to promote chemo-sensitivity in human melanoma Margaret Grant Dr. K.A. Kiejda,Prof. P. Hersey
16. 2006 2009 Trials Co-Ordinator Cancer Institute, NSW PI
17. 2006 2009 Overcoming resistance of Melanoma to apoptosis Cancer Institute, NSW PI
18. 2006 2009 Cameron Research Fellowship Private Endowment PI
19. 2005 2009 Equipment University of Newcastle RIBG PI
20. 2007 The role of p53 isoforms in chemoresistance of human Melanoma Hunter Medical Research Institute Dr. X.D. Zhang,Prof. P. Hersey,Dr. R.F. Thorne
21. 2007 Characterization of p53 isoforms in human melanoma do they play a role in chemoresistance? Cure Cancer Australia Foundation
22. 2007 The role of p53 isoforms in Newcastle Mater Misericordiae Hospital (Margaret Mitchell Grant) Dr. X.D. Zhang,Dr. K.A. Kiejda,Prof. P. Hersey
23. 2005 2007 Overcoming resistance of human melanoma to chemotherapy NHMRC PI
24. 2006 Infrastructure Grant for Flow Cytometer Cancer Institute, NSW PI
25. 2005 Effect of irradiation on TRAIL-R expression “Wig Week” Research Fund PI
26. 2005 Induction of apoptosis in Melanoma by Docetaxel Margaret Mitchell Research Fund PI
27. 2004 2005 Adjuvant immunotherapy of melanoma with vaccinia melanoma cell lysates RACP Australia Post Medical Research Fund PI
28. 2003 2005 Sensitization of melanoma to TRAIL induced apoptosis NSW SCC PI
29. 2002 2004 Immunotherapy of melanoma with dendritic cell vaccines N.H. & M.R.C PI
30. 2003 Regulation of TRAIL receptor expression in melanoma cells HMRI PI
31. 2002 The role of regulatory T cells in patients with melanoma Leo & Jenny Leukaemia and Cancer Foundation PI
32. 1999 2001 TRAIL induced apoptosis of melanoma NSW SCC PI
33. 2000 TRAIL receptor expression on melanoma in vivo Clive & Vera Ramaciotti Foundation PI
34. 2000 Sensitization of melanoma to TRAIL induced apoptosis Margaret Mitchell PI
35. 1998 2000 Infrastructure grant for melanoma research Melanoma and Skin Cancer Institute (MASCRI) PI
36. 1998 2000 Immunotherapy of melanoma with dendritic cells N.H. & M.R.C PI
37. 1999 TRAIL receptor expression on human melanoma Margaret Mitchell PI
38. 1999 Treatment of melanoma with TRAIL in combination with chemotherapy Cecilia Kilkeary PI
39. 1998 1999 Assessment of photography as an aid to early detection of melanoma in older males by general practitioners N.H. & M.R.C PI
40. 1997 1999 Analysis of immune responses to human melanoma N.H. & M.R.C PI
41. 1997 Analysis of immune responses to human melanoma Kilkeary Foundation PI
42. 1996 1997 Detection of melanoma cells in the circulation N.S.W. State Cancer Council PI
43. 1996 1997 Detection of melanoma cells in the circulation JP Morgan Fund PI
44. 1993 1997 Vaccinia melanoma cell lysates in treatment of melanoma Sydney Melanoma Foundation PI
45. 1996 Detection of melanoma cells in the circulation Kilkeary Foundation PI
46. 1994 1995 Detection of melanoma cells in the circulation N.S.W. State Cancer Council PI
47. 1993 1995 Characterization of inhibitors/cytokines from melanoma cells NBN Telethon PI
48. 1993 1995 Analysis of structures involved in recognition of human melanoma by T cells N.H. & M.R.C PI
49. 1994 Analysis of melanoma antigens recognized by human T cells Clive & Vera Ramaciotti Foundation PI
50. 1990 1993 Ultraviolet radiation in the induction of suppressor cells in melanomas N.H. & M.R.C PI
51. 1992 Investigation of the function of a marker of tumor progression in melanomac Clive & Vera Ramaciotti Foundation PI
52. 1988 1992 Immunotherapy with vaccinia melanoma cell lysates for treatment of patients with bad prognosis melanoma N.S.W. State Cancer Council PI
53. 1989 1991 Analysis of melanoma antigens recognized by human T cells N.H. & M.R.C PI
54. 1987 1989 Monoclonal antibodies in the in vivo diagnosis of human melanoma N.H. & M.R.C PI
55. 1986 1988 Clonal analysis of Interleukin 2 dependent T cells in melanoma patients N.H. & M.R.C PI
56. 1985 1987 Evaluation of monoclonal antibodies in the histological assessment of prognosis in melanoma Hunter Valley Cancer Appeal PI
57. 1985 1986 Effects of ultraviolet irradiation on the immune system in man N.S.W. State Cancer Council PI
58. 1983 1985 Analysis of Interleukin 2 induced cytotoxicity against human tumours N.H. & M.R.C PI
59. 1983 Investigation of the role of interleukin in the treatment of malignancies Sydney Hospital Foundation for Research PI
60. 1983 The role of melanoma antigens in human tumor host relationships N.H. & M.R.C PI
61. 1980 1982 Investigation of hypogammaglobulinaemia in cigarette smokers Tobacco Research Foundation PI
62. 1978 1982 Diagnostic applications of antibodies to human tumour associated antigens National Cancer Institute (USA) Contract PI
63. 1980 1981 The role of suppressor activity against immune responses in the pathogenesis of malignant melanoma N.S.W. State Cancer Council PI
64. 1978 1980 The role of melanoma antigens in human tumor host relationships N.H. & M.R.C PI
65. 1978 1980 Immunological reactivity to acute myeloid leukaemia antigens in man N.H. & M.R.C PI
66. 1979 Immunological studies in melanoma patients Univ. Sydney Cancer Res. Fund PI
67. 1978 1979 Investigation of hypogammaglobulinaemia in patients with C.L.L. N.S.W. State Cancer Council PI
68. 1978 1979 Investigation of tumor escape mechanisms Clive and Vera Ramaciotti Foundation PI
69. 1977 1978 Immunological reactivity of human subjects with acute leukaemia N.S.W. State Cancer Council PI
70. 1977 The role of melanoma antigens in human tumor host relationships N.H. & M.R.C PI
71. 1976 1977 Immunology in the diagnosis and treatment of melanoma N.S.W. State Cancer Council PI
72. 1976 1977 Immunological aspects of melanoma Univ. Sydney Cancer Res. Fund PI


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.